PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma

Modern Pathology

Volumn 20, Issue 3, 2007, Pages 326-330

  Schaffel, Rony ^a   Morais, José C ^a   Biasoli, Irene ^a   Lima, Joana ^b   Scheliga, Adriana ^b   Romano, Sergio ^b   Milito, Cristiane ^a   Spector, Nelson ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Diffuse large B cell lymphoma; Immunohistochemistry; Prognosis; Protein kinase C beta

Indexed keywords

ENZYME ANTIBODY; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA II; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT; SURVIVAL TIME; TISSUE FIXATION;

EID: 33847411128     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800738     Document Type: Article

References (19)

1. Milito CB, Morais JC, Nucci M, et al. Classification of non-Hodgkin's lymphoma: morphological and immunological study of 145 cases. J Bras Patol Med Lab 2002;38:315-324. Available fromWorldWideWeb: 〈http://www.scielo.br/scielo.php?script?sci_arttext&pid= S1676-24442002000400011&lng=en&nrm=iso〉. ISSN 1676-2444.
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
3. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
4. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
5. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
6. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-614.
7. Mischak H, Kolch W, Goodnight J, et al. Expression of protein kinase C genes in hemopoietic cells is cell-type and B cell-differentiation stage specific. J Immunol 1991;147:3981-3987.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-1384.
9. Sáez A-I, Sáez AJ, Artiga M-J, et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613-622.
10. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000;13:193-207.
11. López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. J Clin Oncol 2005;23:2797-2804.
12. Spector N, Milito CB, Biasoli I, et al. P53 expression as a prognostic indicator in hodgkin's lymphoma. J Clin Oncol 2005;23:3158-3159.
13. Briones J, Espinosa I, Bordes R, et al. Membrane expression of PKC-beta 2 protein identifies a sugroup of patients with diffuse large B-cell lymphoma with poor survival [abstract]. In: 9th International Conference on Malignant Lymphoma; 2005 Jun 8-11. Lugano (Switzerland). Ann Oncol (Suppl 5). Oxford Journals: Oxford (England), 2005, p. v.58. Abstract 078.
14. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol 2004;124:151-159.
15. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase isoforms and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279:L429-L438.
16. Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002;195:1647-1652.
17. Teicher BA, Alvarez E, Mendelsohn LG, et al. Enzymatic rationale and preclinical support for a potent protein kinase Cβ inhibitor in cancer therapy. Adv Enzyme Regul 1999;39:313-327.
18. Wu E, Aguiar RCT, Savage KJ, et al. PKCβ: a rational therapeutic target in diffuse large B-cell lymphoma [abstract]. In: 44th Annual Meeting of the American Society of Hematology; 2002 Dec 6-10. Philadelphia (PA). Blood. The American Society of Hematology: Washington DC, 2002, p. 202a. Abstract 757.
19. Robertson M, Kahl B, Vose J, et al. A phase II study of enzastaurin, a protein kinase C-β (PKCβ) inhibitor, in the treatment of relapsed diffuse large B-cell lymphoma (DLBCL) [abstract]. In: 47th Annual Meeting of The American society of Hematology; 2005 Dec 10-13. Atlanta (GA). Blood. The American Society of Hematology: Washington DC, 2005, p. 275a. Abstract 934.